Infobionic™ is an emerging mHealth company with a proprietary wireless remote patient monitoring platform, MoMe™, for superior arrhythmia monitoring and diagnosis. An arrhythmia is an irregular heart beat (rate or rhythm) and 4M Americans suffer from recurrent arrhythmia. Atrial Fibrillation (AF) is the most common form with 200,000 new cases each year. The initial market application will be with physicians who specialize in Electrophysiology.
The Massachusetts General Hospital (MGH), the Technical University of Munich (TUM), and Broadview Ventures, Inc. are collaborating on NIRF-IVUS Molecular Imaging of Atherosclerosis. The improved detection and stratification of high-risk plaques, i.e. atherosclerotic plaques at risk of causing heart attacks and strokes, is an unmet need. Early detection enables earlier intervention, prevention and tailored pharmacotherapy. Farouc Jaffer, MD, PhD, of MGH and Vasilis Ntziachristos, PhD of TUM, in conjunction with Intravascular Imaging Incorporated (“i3”) , are developing and testing prototype devices, software and systems for a comprehensive catheter-based approach to detect high-risk plaques in human arteries.
Ischemia Care is a commercial-stage diagnostic company developing a platform of RNA expression blood tests to determine the cause of ischemic stroke and TIA. ISC’s first test, ISCDX, launched upon the completion of the BASE clinical trial (NCT02014896) which enrolled over 1,700 subjects at 20 major hospitals in the US. ISCDX seeks to characterize the underlying cause of the roughly 35% of incident strokes known as cryptogenic, enabling physicians to better care for their patients and more effectively prevent recurrent strokes. ISCDX was launched commercially in 2019.
Mellitus is dedicated to advancing diabetes detection and monitoring through products based on GCD59, a biomarker of glycemic load that is unique because of its direct relationship to the complications of diabetes. Our premier application is a patient-friendly test for gestational diabetes, enabling more timely intervention to improve the health of both mother and child. We plan to commercialize our products through strategic partners as we expand indications to benefit all individuals with diabetes.